Two Drug Combination Doubled Kidney Cancer Progression-Free Survival

Progression-free survival remains debatable endpoint in cancer trials.

I n recent years the U.S. Food and Drug Administration has approved cancer therapies on the basis of improved progression-free survival (PFS), including several drugs for the treatment of metastatic kidney cancer. Clinicians who treat kidney cancer patients are convinced that the agency made the right move, and some even contend that overall survival (OS) is no longer a useful endpoint in this ...

Chromothripsis and progression-free survival in metastatic colorectal cancer

Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromot...

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

PURPOSE Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. The improvement was modest prompting the search for predictive biomarkers for bevacizumab. EXPERIMENTAL DESIGN Pretreatment training (n=91) and validation (n=114) blood samples were provided by ICON7 patients. Plasma co...

Key Words: multi drug resistance, breast cancer, metronomic therapy, cancer metabolism, evolution of drug resistance. Running title: Prolonging progression-free survival in breast cancer

Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer

BACKGROUND Small cell lung cancer (SCLC) is an extremely aggressive tumor with a poor clinical course. Although many efforts have been made to improve patients' survival rates, patients who survive longer than 2 years after chemotherapy are still very rare. We examined the baseline characteristics of patients with long-term survival rates in order to identify the prognostic factors for overall ...